PT - JOURNAL ARTICLE AU - Stefano, Leon Di AU - Ogburn, Elizabeth L. AU - Ram, Malathi AU - Scharfstein, Daniel O. AU - Li, Tianjing AU - Khanal, Preeti AU - Baksh, Sheriza N. AU - McBee, Nichol AU - Gruber, Joshua AU - Gildea, Marianne R. AU - Goldenberg, Neil A. AU - Bennani, Yussef AU - Brown, Samuel M. AU - Buckel, Whitney R. AU - Clement, Meredith E. AU - Mulligan, Mark J. AU - O’Halloran, Jane A. AU - Rauseo, Adriana M. AU - Self, Wesley H. AU - Semler, Matthew W. AU - Seto, Todd AU - Stout, Jason E. AU - Ulrich, Robert J. AU - Victory, Jennifer AU - Bierer, Barbara E. AU - Hanley, Daniel F. AU - Freilich, Daniel AU - , TI - Hydroxychloroquine/Chloroquine for the Treatment of Hospitalized Patients with COVID-19: An Individual Participant Data Meta-Analysis AID - 10.1101/2022.01.10.22269008 DP - 2022 Jan 01 TA - medRxiv PG - 2022.01.10.22269008 4099 - http://medrxiv.org/content/early/2022/01/11/2022.01.10.22269008.short 4100 - http://medrxiv.org/content/early/2022/01/11/2022.01.10.22269008.full AB - Importance Results from observational studies and randomized clinical trials (RCTs) have led to the consensus that hydroxychloroquine (HCQ) and chloroquine (CQ) are not effective for COVID-19 prevention or treatment. Pooling individual participant data (IPD), including unanalyzed data from trials terminated early, enables further investigation of the efficacy and safety of HCQ/CQ.Objective To assess efficacy of HCQ/CQ in patients hospitalized with COVID-19, both overall and in prespecified subgroups.Data Sources ClinicalTrials.gov was searched multiple times in May-June 2020. Principal investigators of US-based RCTs evaluating HCQ/CQ in hospitalized COVID-19 patients were invited to collaborate in this IPD meta-analysis.Study Selection RCTs in which: (1) HCQ/CQ was a treatment arm; (2) patient informed consent and/or individual study IRB approval allowed for data sharing; (3) principal investigators/their institutions signed a data use agreement for the present study; and (4) the outcomes defined in this study were recorded or could be extrapolated.Data Extraction and Synthesis Wherever possible, harmonized de-identified data were collected via a common template spreadsheet sent to each principal investigator, then shared via a secure online data sharing platform to create a pooled data set. When this was not possible, individual study data were harmonized and merged manually. Data were analyzed by fitting a prespecified Bayesian ordinal regression model and standardizing the resulting predictions.Main Outcome(s) and Measure(s) 7-point ordinal scale, measured between day 28 and 35 post-enrollment.Results Eight of 19 trials met eligibility criteria and agreed to participate. Patient-level data were available from 770 participants (412 HCQ/CQ vs 358 control). Baseline characteristics were similar between groups. We found no evidence of a difference in ordinal scores between days 28 and 35 post-enrollment in the pooled patient population (odds ratio, 0.97; 95% credible interval, 0.76-1.24; higher favors HCQ/CQ), and no convincing evidence of meaningful treatment effect heterogeneity among prespecified subgroups. Adverse event and serious adverse event rates were numerically higher with HCQ/CQ vs control (0.39 vs 0.29 and 0.13 vs 0.09 per patient, respectively).Conclusions and Relevance The findings of this IPD meta-analysis reinforce those of individual RCTs that HCQ/CQ is not efficacious for treatment of COVID-19 in hospitalized patients.Question Does hydroxychloroquine/chloroquine benefit hospitalized patients with COVID-19, overall or within prespecified subgroups?Findings In this individual participant data meta-analysis of 770 hospitalized COVID-19 patients across 8 clinical trials, we did not find evidence of a benefit of hydroxychloroquine/chloroquine, measured by a 7-point ordinal COVID-19 severity score at 28-35 days post-enrollment, in the pooled study population. We also found no substantial treatment effect heterogeneity among prespecified patient subgroups.Meaning This study supports the consensus that hydroxychloroquine/chloroquine should not be used to treat hospitalized patients with COVID-19.Competing Interest StatementDr. Baksh, Ms. McBee, and Dr. Hanley reported receiving research funding from the Department of Defense for clinical trials of convalescent plasma for COVID-19 outside the submitted work. Dr. Goldenberg reported receiving salary support from the National Institutes of Health (NIH) National Center for Advancing Translational Sciences via a Johns Hopkins Clinical and Translational Science Award. Dr. Bennani reported being a site investigator for Janssen outside the submitted work. Dr. Brown reported service as chair of a data and safety monitoring board for a Hamilton clinical trial in respiratory failure; fees paid to Intermountain Healthcare from Faron Pharmaceuticals and Sedana Pharmaceuticals for steering committee service for a clinical trial in acute respiratory distress syndrome; research grants to Intermountain Healthcare from Janssen, NIH, Centers for Disease Control and Prevention, and Department of Defense; and royalties from Oxford University Press and Brigham Young University for books on history, religion, and ethics, outside the submitted work. Dr. Clement reported service on a Roche advisory board and as a site investigator for Janssen outside the submitted work. No other disclosures were reported.Clinical Protocols https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42021254261 Funding StatementThis collaboration was supported by the NIH National Center for Advancing Translational Sciences grant U24TR001609. Mr. Di Stefano is supported by an American Australian Association Sir Keith Murdoch Scholarship. Dr. Ogburn is supported by the Johns Hopkins Bloomberg School of Public Health. Dr. Brown and Dr. Buckel were funded by the Intermountain Research and Medical Foundation; Intermountain Heart and Lung Foundation; and Intermountain Office of Research for the HAHPS study. Dr. OHalloran was funded by NIH Clinical and Translational Science Award grant UL1TR002345, and the WU352 study was supported by the Institute of Clinical and Translational Research at the Washington University School of Medicine. Dr. Self and the ORCHID trial were supported by the following grants from the National Heart, Lung, and Blood Institute: 3U01HL123009-06S1, U01HL123009, U01HL122998, U01HL123018, U01HL123023, U01HL123008, U01HL123031, U01HL123004, U01HL123027, U01HL123010, U01HL123033, U01HL122989, U01HL123022, and U01HL123020. Sandoz, a Novartis division, supplied the hydroxychloroquine and placebo used in the ORCHID trial. Dr. Stout was funded by Duke University School of Medicine for the NCT04335552 study. Ms. Victory and Dr. Freilich are supported by the Bassett Research Institute. Dr. Bierer is supported by the National Center for Advancing Translational Sciences grant UL1TR002541 and Brigham and Womens Hospital. The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The IRB of Johns Hopkins University (JHU) gave ethical approval for this work. Specifically, the IRB at JHU provided exemption status, stating 'this activity is not human subjects research; no submission to the IRB is required' as well as separate approval for housing the study's data at JHU and for conducting the study's analysis.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.